Neurological comorbidities in psoriasis and psoriatic arthritis: Neuropathic pain, cognitive impairment and cerebrovascular risk
Authors:
- I. K. ThabisimovaITI. K. Thabisimova
- A. R. MamievaAMA. R. Mamieva
- S. Kh. EtteevaSES. Kh. Etteeva
- D. A. MusaevDMD. A. Musaev
- D. Kh. KazharovaDKD. Kh. Kazharova
- S. M. ShokumovaSSS. M. Shokumova
- Z. A. MagkaevZMZ. A. Magkaev
- Ju. G. VerasJVJu. G. Veras
- F. V. KulchievaFKF. V. Kulchieva
- M. M. ShorovaMSM. M. Shorova
- K. A. BadrakovaKBK. A. Badrakova
- A. K. AbazovaAAA. K. Abazova
- 31 May 2026
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 20 (5) , 64-71
Abstract
Introduction. Modern research has convincingly demonstrated that psoriatic disease is associated with an increased risk of various neurological disorders. Neuropathic pain, cognitive disorders, and cerebrovascular complications are of particular clinical importance, significantly affecting the prognosis and management of patients. Aim . To systematize and critically analyze current data on the spectrum of neurological comorbidities in psoriasis and psoriatic arthritis, with an emphasis on neuropathic pain, cognitive impairment, and cerebrovascular risk. Materials and methods . An analytical review of 128 publications indexed in PubMed, Scopus, and Web of Science databases for the period 2018–2025 was conducted. Inclusion criteria: original studies, meta-analyses, and systematic reviews containing quantitative data on neurological manifestations in patients with psoriatic disease. The sources were stratified by types of neurological pathology: peripheral neuropathy, neuropathic pain, central sensitization, anxiety-depressive disorders, cognitive deficits, and cerebrovascular events. Results . The prevalence of neuropathic pain in patients with psoriatic arthritis is 26.6–48.5%, depending on the diagnostic tool used. The relative risk of polyneuropathy in psoriasis was increased 19–fold compared with the control group (RR = 19.00; 95% CI 1.12–322.11). The prevalence of depression and anxiety reaches 20% and 21%, respectively. Cerebrovascular morbidity increased by 22% relative to the general population. The role of the IL-23/Th17 axis in the formation of neuroinflammation and disruption of the integrity of the blood-brain barrier has been revealed. Biological therapy targeting TNF-α, IL-17, and IL-23 demonstrates the potential to reduce neurological comorbidity. Conclusion . Psoriatic disease is a multisystem disorder with a clinically significant neurological component that requires a multidisciplinary approach to patient management.Keywords
This publication has 24 references indexed in Scilit:
- Psoriasis and dementia: A population‐based matched cohort study of adults in EnglandAnnals of Clinical and Translational Neurology, 2025
- Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort studyMuscle & Nerve, 2024
- T cell-mediated skin-brain axis: Bridging the gap between psoriasis and psychiatric comorbiditiesJournal of Autoimmunity, 2024
- Epidemiology of mental health comorbidity in patients with psoriasis: An analysis of trends from 1986 to 2019Psychiatry Research, 2023
- Associations between psoriasis and mental illness: an update for cliniciansGeneral Hospital Psychiatry, 2022
- PsoriasisThe Lancet, 2021
- Increased risk of Alzheimer’s disease in patients with psoriasis: a nationwide population-based cohort studyScientific Reports, 2020
- Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processingClinical Rheumatology, 2019
- Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta‐Analysis of Observational StudiesArthritis Care & Research, 2016
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013